Next Article in Journal
Reactive Oxygen Species Cause Exercise-Induced Angina in a Myocardial Ischaemia-Reperfusion Injury Model
Next Article in Special Issue
The Human-Restricted Isoform of the α7 nAChR, CHRFAM7A: A Double-Edged Sword in Neurological and Inflammatory Disorders
Previous Article in Journal
Droplet Digital PCR for Non-Invasive Prenatal Detection of Fetal Single-Gene Point Mutations in Maternal Plasma
Previous Article in Special Issue
Comment on Kopańska et al. Disorders of the Cholinergic System in COVID-19 Era—A Review of the Latest Research. Int. J. Mol. Sci. 2022, 23, 672
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Reply

Reply to Cafiero et al. Comment on “Kopańska et al. Disorders of the Cholinergic System in COVID-19 Era—A Review of the Latest Research. Int. J. Mol. Sci. 2022, 23, 672”

by
Marta Kopańska
1,*,
Jacek Szczygielski
2,3,
Paulina Bartman
4 and
Agnieszka Banaś-Ząbczyk
5
1
Department of Pathophysiology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland
2
Department of Neurosurgery, Institute of Medical Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland
3
Department of Neurosurgery, Faculty of Medicine, Saarland University, 66-424 Homburg, Germany
4
Students Science Club “Reh-Tech”, University of Rzeszow, 35-959 Rzeszow, Poland
5
Department of Biology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(5), 2822; https://doi.org/10.3390/ijms23052822
Submission received: 24 February 2022 / Accepted: 2 March 2022 / Published: 4 March 2022
(This article belongs to the Special Issue Cholinergic Control of Inflammation)
We have carefully read the Letter to the Editor by Concetta Cafiero, Alessandra Micera, Agnese Re, Beniamino Schiavone, Giulio Benincasa, and Raffaele Palmirotta related to our paper entitled “Disorders of the Cholinergic System in COVID-19 Era—A Review of the Latest Research” [1] published in the International Journal of Molecular Science.
Thank you for your positive feedback and for providing us with topics that extend our article with new reports. In the commentary, the authors drew attention to other aspects of the issues raised in our review (e.g., paying attention to the treatment of elderly or young people with severe course of the disease [2]). We would like to take an opportunity to reply to the authors due to overlapping conclusions, and we also want to update some topics.
The authors conducted a study in which new regions of homology between neurotoxin and SARS-CoV-2 sequences have been identified [3]. Palmirotta et al. [3] noted that the presence of identical or functionally equivalent amino acids is not limited to the 375–390 region as previously described, but it is also present in other areas of the Spike glycoprotein, with a sequence homology of 47/86 aa. The authors also found homology for the Muscarinic toxin-like protein, identified in Bungarus multicinctus (Snake: Many-banded krait; UniPro tKB: Q9W727—3SO8_BUNMU), which exhibits an entirely similar sequence to Neurotoxin homolog NL1. Additionally, they found a homology between the cryptic epitope for the human antibody CR3022 and the 27aa Kappa-conotoxin-like as14a, identified in Conus cancellatus (Cancellate cone; Conus austini; UniPro tKB: P0C6S2—CLEA_CON-CF), with an overall sequence homology of 12/27 aa. Several of the conotoxin sequences that the authors searched in Uni Prot Knowledge Base (UniProtKB) database aligned with the SARS-CoV-2 Spike glycoprotein. The presented data indicate that regions of homology with neurotoxin-like peptides are more frequently and widely present on the Spike glycoprotein than previously suspected [3].
It is also appropriate to pay attention to the intestinal symptoms that arise as a result of COVID-19 infection, as the discovery of the action and penetration of the coronavirus into the gastrointestinal tract will allow for the preparation of new, better therapies targeting the gut microbiota. Inflammatory stimuli cause the release of cytokines and microbes that can cause dysbiosis, which results in the release of intestinal cytokines into the circulation (this increases systemic inflammation caused by COVID-19) [4]. Modulation of the gut microflora is believed to have the potential to alleviate COVID-19 and its related complications, but studies should be conducted to establish the safety and efficacy of probiotics. Once we discover the mechanisms involved in the entry of the coronavirus into the gastrointestinal tract (especially if we understand disease progression), it will be possible to design therapies based on the intestinal microbes, which will likely alleviate/reverse the effects of COVID-19 [5].
We also agree that SARS-CoV-2 has the ability to penetrate through the cholinergic receptors present in ocular tissues. The virus from infected tears can be bound by the conjunctiva, the cornea, or the epithelium of the nasolacrimal duct [6,7,8]. The virus binds to the ACE2 receptors mentioned by the authors, but there are also reports that SARS-CoV-2 may bind to the CD147 receptor (receptor cluster of differentiation 147). Previous studies have confirmed the presence of CD147 in both the tears and conjunctiva, corneal epithelium and endothelium, or in the retinal pigment epithelium. The presence of CD147 was also noticed in cells infected with SARS-CoV-2 [7].
In conclusion, we would like to emphasize once again how important it is to constantly update our knowledge about the cholinergic system and how it is affected by COVID-19. As one can see from both the authors’ comment and our reply, this is a rapidly evolving topic, so we encourage everyone to follow the latest research on this topic.

Author Contributions

Conceptualization, M.K. and A.B.-Z.; writing—original draft preparation, M.K. and P.B.; review and editing, J.S. and M.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kopańska, M.; Batoryna, M.; Bartman, P.; Szczygielski, J.; Banaś-Ząbczyk, A. Disorders of the Cholinergic System in COVID-19 Era—A Review of the Latest Research. Int. J. Mol. Sci. 2022, 23, 672. [Google Scholar] [CrossRef] [PubMed]
  2. Cafiero, C.; Micera, A.; Re, A.; Schiavone, B.; Benincasa, G.; Palmirotta, R. Comment on Kopańska et al. Disorders of the Cholinergic System in COVID-19 Era—A Review of the Latest Research. Int. J. Mol. Sci. 2022, 23, 672. Int. J. Mol. Sci. 2022, 23, 2818. [Google Scholar] [CrossRef]
  3. Cafiero, C.; Micera, M.; Re, A.; Postiglione, L.; Cacciamani, A.; Schiavone, B.; Benincasa, G.; Palmirotta, R. Could Small Neurotoxins-Peptides be Expressed during SARS-CoV-2 Infection? Curr. Genom. 2021, 22, 557–563. [Google Scholar] [CrossRef]
  4. Villapol, S. Gastrointestinal symptoms associated with COVID-19: Impact on the gut microbiome. Transl. Res. 2020, 226, 57–69. [Google Scholar] [CrossRef] [PubMed]
  5. Akour, A. Probiotics and COVID-19: Is there any link? Lett. Appl. Microbiol. 2020, 71, 229–234. [Google Scholar] [CrossRef] [PubMed]
  6. Ho, D.; Low, R.; Tong, L.; Gupta, V.; Veeraraghavan, A.; Agrawal, R. COVID-19 and the Ocular Surface: A Review of Transmission and Manifestations. Ocul. Immunol. Inflamm. 2020, 28, 726–734. [Google Scholar] [CrossRef] [PubMed]
  7. Dockery, D.M.; Rowe, S.G.; Murphy, M.A.; Krzystolik, M.G. The Ocular Manifestations and Transmission of COVID-19: Recommendations for Prevention. J. Emerg. Med. 2020, 59, 137–140. [Google Scholar] [CrossRef] [PubMed]
  8. Matos, A.G.; Sarquis, I.C.; Santos, A.A.N.; Cabral, L.P. COVID-19: Risk of ocular transmission in health care professional. Rev. Bras. Med. Trab. 2021, 19, 82–87. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kopańska, M.; Szczygielski, J.; Bartman, P.; Banaś-Ząbczyk, A. Reply to Cafiero et al. Comment on “Kopańska et al. Disorders of the Cholinergic System in COVID-19 Era—A Review of the Latest Research. Int. J. Mol. Sci. 2022, 23, 672”. Int. J. Mol. Sci. 2022, 23, 2822. https://doi.org/10.3390/ijms23052822

AMA Style

Kopańska M, Szczygielski J, Bartman P, Banaś-Ząbczyk A. Reply to Cafiero et al. Comment on “Kopańska et al. Disorders of the Cholinergic System in COVID-19 Era—A Review of the Latest Research. Int. J. Mol. Sci. 2022, 23, 672”. International Journal of Molecular Sciences. 2022; 23(5):2822. https://doi.org/10.3390/ijms23052822

Chicago/Turabian Style

Kopańska, Marta, Jacek Szczygielski, Paulina Bartman, and Agnieszka Banaś-Ząbczyk. 2022. "Reply to Cafiero et al. Comment on “Kopańska et al. Disorders of the Cholinergic System in COVID-19 Era—A Review of the Latest Research. Int. J. Mol. Sci. 2022, 23, 672”" International Journal of Molecular Sciences 23, no. 5: 2822. https://doi.org/10.3390/ijms23052822

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop